CCO Management Series
Research Priorities in Non-Small-Cell Lung Cancer
Barriers to Clinical Trial Accrual and Recommendations for Improvement |
Module 1 of 5 |
|
|
|
Walter J. Curran, MD, explores barriers to patient accrual in non-small-cell lung cancer clinical trials and recommends strategies to improve patient numbers.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify the primary barriers to patient accrual in non-small-cell lung cancer clinical trials
- Recall current statistics regarding lung cancer in the United States
- Describe the current state of lung cancer clinical trial accrual and prioritization of increasing these numbers
|
Adjuvant and Neoadjuvant Therapy for Early-Stage NSCLC |
Module 2 of 5 |
|
|
|
Topics covered include:
- Introduction
- Adjuvant and Neoadjuvant Chemotherapy
- Targeted Therapies
- Priority Trials in Early-Stage NSCLC
- Treatment of Locally Advanced NSCLC
Learning Objectives
Upon completion of this activity, participants should be able to:
- Review the use of adjuvant and neoadjuvant therapy in the setting of NSCLC
- Discuss reasons for low enrollment in lung cancer clinical trials
- Summarize the use of epidermal growth factor receptor tyrosine kinase inhibitors in patients with NSCLC
|
Screening and Imaging in NSCLC |
Module 3 of 5 |
|
|
|
Topics covered include:
- The Premise of Screening
- Experience From Early Chest Radiography Screening Trials
- Trials Evaluating CT Screening
- Molecular Screening Techniques
- Categories and Staging in NSCLC
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe key clinical trial data regarding computed tomography screening in the setting of NSCLC
- Discuss molecular screening tools in NSCLC
- Define staging classifications of NSCLC
|
First-Line and Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer |
Module 4 of 5 |
|
|
|
Topics covered include:
- Epidemiology of Advanced NSCLC
- Current Standard Treatment for Patients With Advanced Disease
- Targeted Agents for the First-Line Treatment of NSCLC
- Optimizing Patient Selection
- Second-Line Treatment Options for Advanced NSCLC
Learning Objectives
Upon completion of this activity, participants should be able to:
- Review clinical trial results of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
- Describe future therapeutic approaches to NSCLC
- Summarize the use of bevacizumab and cetuximab in the treatment of advanced NSCLC
|
Novel Therapeutic Approaches |
Module 5 of 5 |
|
|
|
Topics covered include:
- Introduction
- Epidermal Growth Factor Receptor Inhibitors
- Antiangiogenic Agents
- Multikinase Inhibitors
- PI3K-Akt-mTOR Pathway
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the use of epidermal growth factor inhibitors in the setting of NSCLC
- Discuss clinical data regarding the use of bevacizumab in NSCLC
- Summarize the use of kinase inhibitors in patients with lung cancer
|
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
In association with
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|
|